Clinical Quality (GCP)
Sponsor oversight, subject protection, and the credibility of trial data.
What a domain score is not
A domain is one of the axes SPEQ’s assessment scores, on SPEQ’s own five-stage progression. It is a labelled synthesis, not the FDA’s Quality Management Maturity rating, and a score here is a self-assessment — nobody but you has rated your organization.
Sponsor oversight and subject protection are the core of Good Clinical Practice. Inadequate oversight of CROs and delegated activities, and failures in informed-consent control, are recurring inspection findings that can invalidate trial data outright — the highest-stakes outcome in the clinical space.
Maturity in clinical quality is the shift from monitoring everything to monitoring what matters, and from correcting findings to designing the trial so the finding is unlikely. A low-maturity operation verifies source data exhaustively and discovers protocol deviations at closeout; a mature one identifies the data and processes critical to participant safety and result reliability at the design stage, monitors against those, and treats a deviation as information about the trial rather than as a document to file.
- Identify the critical data and processes before the first participant is enrolled, and let that list drive the monitoring plan rather than the other way round.
- Make protocol deviations visible while the trial is running. A deviation log assembled at closeout is a reconstruction, and it cannot change anything.
- Keep the trial master file contemporaneous — a file that would reconstruct the conduct of the study without anyone present is the standard, and assembling it before an inspection announces when it was assembled.
- Treat vendor and site oversight as owned work with visibility, not as a contract with reports attached.
Time from deviation occurrence to record is the most diagnostic single number; if it clusters near closeout, oversight is retrospective. Then: query rates by site and by form, which locate ambiguity in the protocol rather than fault in the site; and the proportion of monitoring findings that were already known to the site, which says whether monitoring is discovering or confirming.
The observable behaviours that place a site at each level — what a practitioner or inspector would actually see — and the concrete move that carries it to the next.
- ·Monitoring is inconsistent and undocumented
- ·Data quality problems are found late
- ·No defined risk basis for oversight
TO ADVANCE →Establish GCP SOPs and a defined monitoring approach for trials.
- ·100% source-data verification regardless of risk
- ·Findings are logged but trends are not analysed
- ·TMF is reconstructed near database lock, not maintained
TO ADVANCE →Adopt risk-based monitoring/quality management (ICH E6(R2)/(R3)) focused on what matters to participants and data.
- ·Monitoring intensity follows risk, not habit
- ·Critical-to-quality factors and KRIs are defined up front
- ·TMF is maintained contemporaneously
TO ADVANCE →Add centralised/statistical monitoring so signals are detected across sites, not one visit at a time.
- ·Central statistical monitoring flags anomalous sites/patterns
- ·KRIs are trended and trigger proportionate action
- ·Quality tolerance limits are defined and monitored
TO ADVANCE →Move toward predictive quality — design quality into the protocol and anticipate risk.
- ·Quality-by-design at the protocol stage
- ·Predictive analytics anticipate site and data risk
- ·A learning system feeds each trial’s design from the last
- A risk-based monitoring plan with defined key risk indicators and a rationale for monitoring intensity
- Evidence that a monitoring signal (a KRI trend, a finding) drove a documented action
- Trial master file completeness and currency for a named study
Want the specific artifacts that move your score up? The Comprehensive assessment turns your domain scores into a prioritised, personalised remediation plan.
The observable evidence a practitioner — or an inspector — would expect at each maturity level. Drawn from the assessment questions themselves. This domain is scored in the Comprehensive assessment, whose questions need a free account. Sign in to take it →
- ›Inadequate sponsor oversight of CROs or delegated activities — no documented vendor governance.
- ›Informed-consent version-control failures; consent not reconciled to the IRB/IEC-approved version.
- ›Protocol deviations not captured, assessed for impact, or reported.
- ›Monitoring not risk-based around the critical-to-quality factors of ICH E6(R3).